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1.   Zusammenfassung/ Summary 
Der Nachweis der felinen Leukämievirus (FeLV) Infektion erfolgt meistens mittels p27 
Antigen ELISA. Es gibt jedoch p27-negative Katzen, welche provirus-positiv im Blut sein 
können. Das Risiko einer FeLV Übertragung durch provirus-positives Blut wurde bisher 
nicht untersucht. Das Ziel dieser Studie war es, dieses Risiko zu erforschen. Fünfzehn 
zehn Wochen alte spezifiziert pathogen freie (SPF) Katzenwelpen wurden zufällig in 
drei Gruppen eingeteilt: Die Katzen der Gruppe A erhielten Blut von einer provirus-
positiven Spenderkatze, Gruppe B von einer provirus-positiven und viralen RNA 
positiven Katze und Gruppe C von einer nicht-infizierten SPF Katze. Nach der 
Transfusion wurden alle Katzen der Gruppe A und B positiv für Provirus und virale RNA. 
In der Gruppe A wurden alle Katzen und in der Gruppe B drei Katzen p27-positiv. Die 
Katzen aus der Kontrollgruppe blieben FeLV-negativ. Bemerkenswerterweise wurden 
die Katzen der Gruppe A später provirus-positiv als diejenigen der Gruppe B; sie 
zeigten jedoch einen schlechteren Infektionsausgang (höhere FeLV-Bürden) als Gruppe 
B. Zwei Katzen der Gruppe A wurden persistierend infiziert. Unsere Resultate zeigen 
erstmals, dass FeLV durch Bluttransfusion mit provirus-positivem, antigen-negativem 
Blut auf naive Empfänger übertragen werden kann. Aufgrund unserer Resultate 
empfehlen wir Blutspender-Katzen mittels PCR auf FeLV Provirus zu testen. 
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Cats with suspicion of feline leukemia virus (FeLV) infection are commonly tested for 
antigenemia by p27 ELISA. However, many p27 negative cats test FeLV provirus 
positive in the blood. So far, the risk of a FeLV transmission via provirus-positive blood 
has not been evaluated. The aim of this study was to explore this risk. Fifteen ten-week 
old specified pathogen free (SPF) kittens were randomly assigned to three groups: five 
cats (group A) received blood from a FeLV provirus positive cat, five cats (group B) 
were transfused with blood from a provirus and viral RNA positive cat and five control 
cats (group C) received SPF blood. All cats in groups A and B turned provirus and 
plasma viral RNA positive post transfusion. Moreover, all cats in group A, and three cats 
in group B became p27 positive. All cats in group C stayed FeLV negative. Remarkably, 
cats in group A turned FeLV positive later than cats in group B but had a graver 
infection outcome (higher FeLV loads); two cats in group A became persistently 
infected. Our results demonstrate for the first time that FeLV infection can be 
transmitted via blood transfusion of blood from FeLV provirus positive, antigen negative 
cats to naïve recipients. Based on our results we highly recommend screening blood 
donors for FeLV provirus by PCR prior to blood transfusion.  
2. Introduction 
The feline leukemia virus (FeLV) was discovered in 1964 and belongs to the family of 
gammaretroviridae (Jarrett, Crawford et al. 1964). FeLV is naturally occurring worldwide 
in domestic cats and some related small felids (Hoover and Mullins 1991), 
(Leutenegger, Hofmann-Lehmann et al. 1999). Retroviral infections are of veterinary as 
well as human medical interest as an important animal model for AIDS and tumor 
research (Onions 1985; Miyazawa 2002). FeLV infection can induce both 
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cytoproliferative (tumors) and cytosuppressive diseases (immunodeficiency, and 
myelosuppression) with fatal outcome (Post JE 1980). 
For FeLV infection a variety of outcomes has been demonstrated. They are influenced 
by different host and virus factors, such as age and the immune system status of the cat 
as wells as the strain, subtype and dose of the virus (Hoover and Mullins 1991). The 
spectrum of different infection outcomes is classified into: abortive (no virus detection 
after exposure), regressive (p27 negative, provirus positive after or without transient 
antigenemia), progressive (provirus positive, plasma viral RNA positive, persistently p27 
positive, virus isolation positive) and atypical infection (seroconversion, provirus 
negative, p27 negative) (Torres, Mathiason et al. 2005; Hofmann-Lehmann, Cattori et 
al. 2008; Major, Cattori et al. 2010). In addition, latent non-productive infection 
characterized by the absence of viremia and the persistence of the virus in the bone 
marrow can be identified in cats following regressive infection (Post JE 1980; Rojko, 
Hoover et al. 1982; Madewell and Jarrett 1983). Latent infections are usually resolved 
within a few months of exposure to FeLV but have been detectable in some cats up to 
30 months after infection (Pacitti and Jarrett 1985). While persistently infected cats 
usually succumb to FeLV-associated diseases (anemia, immunosuppression, and 
neoplasia), cats with regressive infections overcome viremia usually after a few weeks 
and remain provirus positive (Hofmann-Lehmann, Cattori et al. 2007). The clinical 
importance of the provirus-positive status is still unclear, it may well be essential for 
solid protection and long-lasting maintenance of protective immunity (Hofmann-
Lehmann, Cattori et al. 2008). On the other hand, reactivation of the infection with 
developing of FeLV associated diseases might occur as had been observed for at least 
some FeLV antigen-negative, provirus positive cats (Post JE 1980; Rojko, Hoover et al. 
1982; Madewell and Jarrett 1983; Hofmann-Lehmann, Cattori et al. 2007; Helfer-
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Hungerbuehler, Cattori et al. 2010). PCR is necessary to detect provirus-positive cats, 
while p27 antigen can be determined by ELISA and was found to be a marker for 
viremia in most but not all cats (Jarrett, Golder et al. 1982). The proviral DNA is 
integrated into the cat’s genome, so it is unlikely to be cleared throughout the infection. 
In provirus positive but p27 negative cats no replicating virus is detectable using virus 
isolation. However, FeLV may retain the potential for replication in provirus positive cats 
for many years (Helfer-Hungerbuehler, Cattori et al. 2010). In addition, plasma viral 
RNA could be detected in the absence of antigenemia in some provirus positive cats 
(Cattori, Tandon et al. 2006; Hofmann-Lehmann, Tandon et al. 2006; Hofmann-
Lehmann, Cattori et al. 2007). Thus, at least a part of the proviral DNA in these cats 
was transcriptionally active (Hofmann-Lehmann, Cattori et al. 2008). In cats with 
regressive infection only certain blood subsets, such as CD4+ and B lymphocytes, are 
provirus-positive compared to persistently infected cats were provirus was found in all 
leukocyte subsets (Pepin, Tandon et al. 2007; Cattori, Pepin et al. 2008). The 
prevalence of provirus positive but p27 negative cats varies among different 
investigated cat populations and was found to be between 1.2% (Englert, Lutz et al. 
2012) and 10% (Hofmann-Lehmann, Huder et al. 2001). 
FeLV is transmitted horizontally, mainly via saliva from persistently infected cats and 
vertically from infected queens to their kittens. The virus is also detectable in different 
body fluids, such as feces, urine, milk and blood (Francis, Essex et al. 1977; Pacitti, 
Jarrett et al. 1986; Cattori, Tandon et al. 2009; Gomes-Keller, Gonczi et al. 2009). 
Therefore, blood sucking parasites and blood transfusions should also be considered as 
potential infection routes (Hardy, Old et al. 1973). Therapeutic blood transfusions of 
blood from FeLV viremic cats can cause iatrogenic transmission of FeLV with the high 
risk of developing FeLV associated diseases (Hardy, Old et al. 1973), especially 
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because blood transfusion recipients may be highly susceptible to infections due to pre-
existing severe clinical conditions and possible immunosuppression. Common causes 
for blood transfusion in cats are hemorrhage (trauma, peri- or postoperative bleeding, 
gastrointestinal bleeding, abdominal neoplasia, coagulopathies, thrombocytopenia), lack 
of erythropoesis and primary immune-mediated hemolytic anemia (Barfield and 
Adamantos 2011). Clinical cases of intense flea burden, hepatic necrosis or neonatal 
isoerythrolysis are causing anemia in kittens so that a blood transfusion is required for 
therapy (Barfield and Adamantos 2011). In veterinary medicine fresh whole blood is 
most commonly used for blood transfusions, composed of red blood cells, white blood 
cells, platelets, the coagulations factors, albumin and immunoglobulins (Chiaramonte 
2004; Godinho-Cunha, Ferreira et al. 2011). Blood transfusions containing fresh whole 
blood is indicated when several blood components are required as coagulation effect, 
severe thrombocytopenia or acute hemorrhage occurs (Lanevschi and Wardrop 2001; 
Chiaramonte 2004; Godinho-Cunha, Ferreira et al. 2011).  
So far, the risk of a FeLV transmission with provirus-positive blood has not been 
evaluated. However, intradermal inoculation plasmid DNA carrying the FeLV-A provirus 
(Rickard/FRA) led to productive FeLV infection (Chen, Bechtel et al. 1998). Therefore, 
whole blood including white blood cells carrying the FeLV provirus might be infectious, 
when transfused to a susceptible cat. 
With the growing importance of feline blood transfusions, the public awareness 
increases, and in turn the demand for high-quality blood products (Kaufman 1992). 
Blood banks are already present in North America and it is likely that in future feline 
blood products will be available in other countries (Barfield and Adamantos 2011). 
Therefore, the screening management of blood donors needs to be employed and 
updated to further guarantee blood safety. To date, for FeLV the screening of the blood 
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for FeLV antigen by ELISA is recommended prior to transfusion (Wardrop, Reine et al. 
2005). So far, no data was available concerning the risk of a potential transmission of a 
productive FeLV infection via provirus positive blood.  
The aim of this study was to test the hypothesis that FeLV infection can be transmitted 
via blood transfusion from a FeLV provirus-positive but antigen negative blood donor to 
a naïve recipient.  
3. Materials and methods 
3.1 Animals 
Fifteen, 8 weeks-old SPF male kittens (blood transfusion recipients) and three castrated 
adult male SPF cats (blood donors) at the age of one year (Liberty Research, Waverly, 
NY, USA) were included in this study. Animals were kept in a confined university facility 
under barrier condition and optimal ethological and hygienic conditions, as previously 
described (Museux, Boretti et al. 2009; Geret, Riond et al. 2011). All experiments were 
performed according to the Swiss law and were officially approved by the veterinary 
office of the canton of Zurich (160/2010). Prior to the start of the experiment, each cat 
was clinically examined, blood and plasma samples, conjunctival, oropharyngeal, and 
rectal swabs were collected and tested to verify the cat’s SPF status, as previously 
described (Museux, Boretti et al. 2009). In addition, serum samples were tested for 
antibodies to feline calicivirus, feline herpes virus and feline parvovirus by 
immunofluorescence assay, as described (Hofmann-Lehmann, Fehr et al. 1996). 
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3.2  Experimental design and blood transfusion 
Experimental setup 
After arrival, the kittens were adapted to the new environment and the care persons for 
two weeks. During this period the cats were trained for easy handling and blood 
collections without anesthesia. The kittens were randomly assigned to three groups (A, 
B, and C) of five kittens. At the age of ten weeks the 15 kittens received the blood 
transfusion (see also below). The cats in group A received blood from a FeLV provirus-
positive, plasma viral negative, and p27 negative cat; cats in group B were transfused 
with blood from a provirus-positive, plasma viral RNA positive and p27 negative cat and 
cats in the control group C received blood from a FeLV-negative naïve SPF cat. Each 
kitten received a total volume of 10 ml of whole blood (Table 1). 
Blood typing 
The blood type of each cat was determined prior to the experiment using EDTA 
anticoagulated blood and a commercial gel column technique (ID-Gel Test Feline A + B 
Typing; DiaMed AG, Cressier sur Morat, Switzerland). 
Cross match 
A standard saline-agglutination crossmatching procedure was performed at 37 °C with 
blood from all recipients and blood donors prior to the blood transfusion (Wardrop 
2010). The blood from each recipient cat was crossmatched with the blood from the 
corresponding blood donor. 
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Table 1: Experimental setup, recipients and transfused blood 
* Volume per recipient 
 
Blood collection for blood transfusion and baseline analysis 
The three adult blood donor cats (GBX3, GCN4, GCN5; Table 2) were anesthetized with 
10 mg/kg ketamin (Narketan®, Vétoquinol AG, Belp, Switzerland) and 0.1 mg/kg 
midazolam (Dormicum®, Roche Pharma AG, Reinach, Switzerland) intramuscularly. 
Then, 50 ml of blood were collected into a syringe containing 7 ml of the anticoagulants 
citrate phosphate dextrose adenine (CPDA-1, Fenwal, Lake Zurich, IL, USA). The 
collected blood from every blood donor was subsequently distributed into five syringes 
each containing finally 10 ml of anticoagulated blood (one syringe for each cat). In 
addition, blood was collected at the same time for baseline analysis performing 
complete hematology, clinical chemistry, quantitative real-time TaqMan PCR for FeLV 
provirus, RT-PCR for plasma viral RNA and p27 ELISA (see below). Subsequently, the 
donor cats received a substitution of warmed 50 ml Ringer-Lactat solution (Fresenius 
Group Recipient 
cats 
Transfused blood: 
Volume (ml)* 
 
Provirus 
 
Viral RNA 
 
p27 
A HBW2 
HBZ3 
HCC1 
HCC4 
HCD1 
10 positive negative negative 
B HBU1 
HBW1 
HBZ1 
HBY1 
HCC3 
10 positive positive negative 
C HBU2 
HCD2 
HCC2 
HBZ2 
HBV1 
10 negative negative negative 
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Kabi, Stans, Switzerland) to prevent hypovolemia; the cats were monitored until 
recovery from anesthesia. 
Characterization of the transfused blood 
The cats in groups A and B (GCN4), received blood from two experimentally FeLV-
A/Glasgow-1 infected cats, GBX3 and GCN4, respectively (Table 2). These two cats 
had been exposed to FeLV at the age of 19-21 weeks, as described previously (Bösch 
2012). Briefly, each cat was inoculated intraperitoneally with cell culture supernatant 
containing 0.8 x 106 focus forming units (FFU) of FeLV-A/Glasgow-1 (Jarrett, Laird et al. 
1973) in a volume of 1 ml. In week 6 after the first exposure, the cats received a second 
intraperitoneal virus challenge with 1.7 x 106 FFU of FeLV-A/Glasgow-1 in a volume of 
1.8 ml cell culture supernatant. The two FeLV-infected cats underwent a regressive 
infection with undetectable antigenemia. At the time of blood collection for the blood 
transfusion they were 42 weeks after experimental infection (Bösch 2012). The blood 
donor for group C was a naïve adult SPF cat (GCN5); (Table 2). 
Table 2: Characterization of the transfused blood: quantification of the FeLV 
loads 
* Calculated using the feline albumin copy numbers determined by real time PCR 
 
 
Group of 
recipient 
cats  
Donor cats FeLV provirus 
(copies/cell)* 
FeLV plasma viral RNA 
(copies/ml plasma) 
p27 Virus 
isolation 
A GBX3 0.002  negative 
 
negative  negative  
B GCN4 0.031  175,464  negative  negative  
C GCN5 negative negative 
 
negative  negative  
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Blood transfusion 
The kittens were anesthetized with Ketamin/Midazolam (10 mg/kg; 0.1 mg/kg, 
Vétoquinol AG, Roche Pharma AG) intramuscularly. Prior to the blood transfusion, 10 
ml of whole blood was collected from the kittens for baseline analysis and to prevent 
circulatory volume overload. Thereafter, 10 ml of the blood from the respective blood 
donor was transfused slowly to each recipient cat (Tables 1 and 2). During and after the 
blood transfusion the kittens were monitored for heart rate, respiratory rate, 
temperature, clinical signs of urticaria and vomiting potentially associated with a 
transfusion reaction or anesthesia incident. 
3.3  Clinical examination and sample collection 
Throughout the observation period weekly clinical examinations including monitoring of 
the general condition, the body temperature and palpation of the lymph nodes were 
performed by veterinarians. In addition, the general condition of the cats was monitored 
daily by a veterinarian and the animal care takers. EDTA anticoagulated blood samples 
and oral swabs were collected prior to and at the day of the blood transfusion (week 0) 
and weekly thereafter for 15 weeks post transfusion. A bone marrow aspirate was 
collected from each recipient cat as described below in week 17 post transfusion. From 
the two FeLV infected blood donor cats a bone marrow collection was performed in 
week 18 post transfusion (week 60 post infection). All recipient and blood donor cats 
stayed in the facility after the end of this study and were monitored continuously by a 
veterinarian. Clinical examination, hematology, blood chemistry analyses and p27 
ELISA were performed at regular intervals for 65 weeks.  
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3.4  Hematology 
White blood cell differential and complete hemograms were performed using a Sysmex 
XT-2000iV (Sysmex Corporation, Kobe, Japan) (Riond, Weissenbacher et al. 2011). 
Diff-Quick-stained (Medion Diagnostics, Dudingen, Switzerland) smears were evaluated 
by light microscopy for leukocyte differentiation. In a case of severe anemia manual 
reticulocytes (RET) counts were performed by enumerating the RETs as a percentage 
of 1,000 mature red blood cells RBCs using a standard method based on Brilliant Cresyl 
Blue (SIGMA-ALDRICH, Steinheim, Germany) stained blood smears (Cossandi and 
Maggiora 1952). Only the aggregated RETs, which represent the more immature cells, 
characterized by large clumps or strands of precipitated nucleoprotein (Perkins, 
Grindem et al. 1995), were counted. Absolute values of RETs were calculated by 
multiplying the microscopically determined fraction of RETs by the RBC count from the 
Sysmex XT-2000iV (Sysmex Corporation). 
3.5  Clinical chemistry and serum protein electrophoresis 
Clinical chemistry was performed using a Cobas Integra 800 system (Roche 
Diagnostics, Rotkreuz, Switzerland) at the time point of the blood transfusion (week 0; 
prior to the transfusion) and in case of the appearance of clinical signs. Serum 
biochemistry analysis included bilirubin, glucose, blood urea nitrogen, creatinine, 
protein, albumin, cholesterol, alkaline phosphatase, aspartate aminotransferase, alanine 
aminotransferase, lipase, sodium, chloride, potassium, phosphorus and calcium. 
Serum protein electrophoresis was performed in one cat in week 8 with 
hyperproteinemia (HCC1, group A) using a semi-automated agarose gel electrophoresis 
system (Hydragel-Hydrasis 7 Protein kit,  Sebia PN 4100, Issy-les-Moulineaux,France) 
according to the procedure described by (Riond, Wenger-Riggenbach et al. 2009). 
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3.6  Nucleic acid extraction and quantification 
Proviral DNA 
Genomic DNA was extracted from 100 µl buffy coat that was obtained from 1 ml of 
EDTA anticoagulated blood using the QIAamp Blood Kit (Qiagen, Hombrechtikon, 
Switzerland) following the manufacturer’s recommendations. DNA was eluted in 100 µl 
of elution buffer and the samples were stored at -20°C until further use. Negative 
extraction controls, consisting of 100 µl of phosphate-buffered saline (PBS) were tested 
in parallel to monitor for cross-contamination. Total FeLV provirus loads were quantified 
by TaqMan PCR (U3 region), as described (Tandon, Cattori et al. 2005) using 5 μl of 
TNA and the following modifications: the TaqMan® Fast Universal PCR Master Mix 
(Applied Biosystems, Foster City, CA, USA) was used in an ABI 7500 sequence 
detection system (Applied Biosystems). The thermocycling conditions consisted of an 
initial denaturation of 20 s at 95 °C, followed by 45 cycles of 95 °C for 3 s and 60 °C for 
45 s. Negative and positive PCR controls were included with each run. Provirus loads 
were normalized to feline albumin copy numbers (Helfer-Hungerbuehler, Widmer et al. 
2013). 
Plasma viral RNA 
Total nucleic acid (TNA) was extracted from 200 µl EDTA plasma using the MagNA 
Pure LC Total Nucleic Acid Isolation Kit (Roche Diagnostics). TNA was eluted in 90 µl of 
elution buffer and stored at -20°C until PCR testing was performed. During all 
extractions, negative controls consisting of 200 µl of PBS were concurrently prepared 
with each batch of samples. TNA was analyzed by real-time TaqMan RT-PCR, as 
described previously (Tandon, Cattori et al. 2005), using 5 μl of TNA and the 
SuperScriptTM III Platinum® One-Step Quantitative RT-PCR System (Invitrogen, Basel, 
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Switzerland) on an ABI 7500 sequence detection system (Applied Biosystems). 
Negative and positive PCR controls were concurrently included with each run. Plasma 
viral RNA loads were calculated as copies per milliliter of blood. 
Viral RNA in saliva 
The oral swabs were processed as described using 200 μl of PBS to extract TNA from 
the saliva swabs (Gomes-Keller, Tandon et al. 2006), and 5 μl of TNA was analyzed by 
real-time TaqMan PCR for plasma viral RNA, as previously described (Tandon, Cattori 
et al. 2005). 
3.7 Serological assays 
EDTA-anticoagulated plasma samples were analyzed for the presence of p27 antigen 
and for antibodies to FeLV whole virus as follows: the p27 antigen was determined 
using a sandwich ELISA, as previously described (Lutz, Pedersen et al. 1983). Results 
are represented as percentages of a defined positive control (plasma sample from a 
persistently FeLV-infected cat), which was considered 100%. Samples reaching > 4 % 
of the positive control signal were considered positive (Hofmann-Lehmann, Huder et al. 
2001). Anti-FeLV whole virus antibodies were measured by ELISA using 500 ng of 
gradient purified antigen per well (FeLV produced in FL-74 cells), as described 
previously (Lutz, Pedersen et al. 1980). The plasma samples were diluted 1:100 and the 
goat anti-cat IgG (Jackson, Immunoresearch Laboratories Inc., Baltimore, USA; 0.8 
mg/ml) were used in a dilution of 1:3,000. 
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3.8  Isolation of FeLV using QN10S cells 
Heparin plasma samples for virus isolation were collected in week 5 post transfusion. 
Isolation of FeLV was performed as described (Jarrett and Ganiere 1996) with the 
following modifications: 4 x 104 QN10S cells were seeded per well, using a 12-well 
cluster plate (TPP; 24-well tissue culture plate, TPP Techno Plastic Products AG, 
Trasadingen, Switzerland). Cells were cultivated in 1 ml of cell culture medium 
supplemented with 4 µg/ml Polybrene (SIGMA-ALDRICH, Buchs, Switzerland). The cell 
culture medium consisted of Dulbecco’s MEM containing HEPES buffer, 10% fetal calf 
serum (FCS; BioConcept, Allschwil, Switzerland), 1 mM sodium pyruvate, 2 mM L-
glutamine, 400 U/ml penicillin, and 400 µg/ml streptomycin (Invitrogen, GIBCO Paisley, 
Scotland, UK). The QN10S cells were incubated with 200 µl of lithium heparin 
anticoagulated feline plasma. After two hours, the supernatant was replaced with fresh 
medium. Development of cytopathic effects were monitored daily. At day 7, the p27 
antigen was quantified in the cell culture supernatant using a sandwich ELISA (Jarrett 
and Ganiere 1996). 
3.9  Bone marrow cell culture 
A bone marrow aspirate was collected of the proximal humerus from each recipient cat 
at week 17 post transfusion under general anesthesia, as described previously 
(Museux, Boretti et al. 2009). In addition, a bone marrow aspirate was collected using 
identical procedures from each of the two FeLV-infected blood donors 18 weeks after 
the blood for the blood transfusion was collected (week 60 after experimental infection).  
The bone marrow aspirate was prepared for cell culture, as described (Madewell and 
Jarrett 1983), with the following modifications: the bone marrow was collected into 
3.5 ml of transport medium: RPMI 1640 cell culture medium (SIGMA-ALDRICH, Buchs, 
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Switzerland), 200mM L-glutamine, 400 U/ml penicillin, 400 µg/ml streptomycin 
(Invitrogen) and 10% of FCS (BioConcept). Crandell feline kidney (CrFK) cells (20,000 
cells/ml) were cultured in a 24 well-plate (TPP Techno Plastic Products AG). The CrFK 
cells were tested for the absence of FeLV using PCR prior to the start for the 
experiment. Negative controls (cells with medium) were concurrently cultured on each 
plate. At the day of bone marrow collection the CrFK cells were 75% confluent. The 
bone marrow cells were resuspended in medium and co-cultured with the CrFK cells. 
The cell culture medium contained: RPMI, Mc Coys 5A (SIGMA-ALDRICH), 200 mM L-
glutamine, 400 U/ml penicillin, 400 µg/ml streptomycin (Invitrogen), 10% FCS 
(BioConcept) and hydrocortisone 1 µg/ml (SIGMA-ALDRICH). The cultures were 
maintained for 12 weeks and half of the medium was replaced every three days, when 
supernatant was collected for p27 ELISA.  
3.10 Necropsy 
Four of the cats (GCN4, HBU1, HCC3 and HBW2) had to be euthanized for humane 
reasons and underwent necropsy and histopathological examination. Tissues for 
histology were fixed in 10% buffered formalin and processed by standard procedures. 
Samples concurrently taken for further analyses were snap-frozen in liquid nitrogen and 
stored at -80°C until further use. 
3.11 Immunohistology 
Tissue sections were tested to identify B and T cells using a CD3 T-cell marker (M7254, 
DAKO) and the B-cell marker for CD79 (M7051, DAKO; RB-90-13-P, Labvision, Thermo 
Fisher Scientific, Fremont, USA). 
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3.12 Statistics 
Statistical analyses were performed using GraphPad Prism for Windows, Version 4.03 
(GraphPad software, San Diego, CA). Changes over time (same group, two different 
time points) were tested using the Wilcoxon signed rank test for paired samples (pw). 
Frequencies were compared using the Fisher’s exact test (pF). Differences between 
group A and B were compared using the Mann-Whitney U-test (pM). A p-value < 0.05 
was considered to be statistically significant. Reference ranges for hematological and 
clinical chemistry parameters, as well as serum protein electrophoresis, were 
determined using identical methods as described above and blood samples from 58 
clinically healthy cats. The reference ranges are given as 5% and 95% quantiles. 
4. Results 
4.1  Verification of SPF status and blood transfusion 
The SPF status was confirmed prior to the start of the experiment; all cats were found to 
be negative for all tested infections. All cats included in the study were of blood type A 
and the recipient cats were identified to be compatible with the donors in the cross 
match. During and after the blood transfusion no adverse reactions in all blood donor 
and recipient cats were observed.  
4.2 FeLV provirus, plasma viral RNA and p27 antigen detection 
FeLV provirus   
All cats in groups A and B became FeLV provirus positive; all cats in the negative 
control group C remained negative (Figures 1 and 3). The cats in group B turned 
significantly earlier FeLV provirus positive than the cats in group A: in week one post 
transfusion all cats in group B were already provirus positive, while none of the cats in 
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group A was positive (pF = 0.0079; Figure 1). In group A, four cats (HBZ3, HCC1, 
HCC4, HCD1) became FeLV provirus positive two weeks post transfusion (Figure 1). 
One cat (HBW2) in group A turned provirus positive for FeLV in week three post 
transfusion (Figure 1). The proviral loads in groups A and B showed significant 
differences in weeks 1, 2, 7 to 12 and week 15 post transfusion. In the first two weeks 
post transfusion the proviral loads were significantly higher in group B than in group A 
(Figure 3b, pM = 0.0079, 0.0317), in accordance that the cats in group B turned earlier 
positive than the cats in group A. However, in weeks 7 to 12 (pM = 0.0317, 0.0159, 
0.0317, 0.0159, 0.0317, 0.0079) and week 15 (pM = 0.0317) the proviral loads became 
significantly lower in the cats in group B compared to those in group A (Figure 3a).  
Plasma viral RNA  
All cats in groups A and B turned also plasma viral RNA positive; in the control group C, 
none of the cats was plasma viral RNA positive at any time point (Figure 1 and 4). In 
three cats in group A (HCC1, HCC4, HCD1) plasma viral RNA could be detected in the 
first week post transfusion. The cat HBZ3 turned plasma viral RNA positive in week 2 
and in cat HBW2 plasma viral RNA was detectable in week 4 post transfusion (Figure 
1). All cats in group B became plasma viral RNA positive in the first week post 
transfusion (Figure 2). Three cats in group B had plasma viral loads below the detection 
limit by week 15 post transfusion, while all cats in group A stayed plasma viral RNA load 
positive (Figure 1). The plasma viral RNA loads were significantly higher in cats in group 
B compared to those in group A at week 1 post transfusion (pM = 0.0079, Figure 4b). 
However, subsequently, the cats in group B had lower plasma viral RNA loads than the 
cats in group A (significantly lower in weeks 4 and 7 to 11 (pM ≤ 0.0317), (Figure 4a). 
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Figure 1: Outcome of FeLV infection in the recipient cats post transfusion. Plasma 
viral RNA and provirus results from blood in the five cats in group A (a), the five cats in 
group B (b) and the five cats in the negative control group C (c). In Group B provirus 
was detectable significantly earlier (at week 1) than in group A (pF = 0.0079). 
 
P27 antigen 
In group A, all cats were p27-positive at some time points post transfusion (Figure 2). 
Two of five cats in group A became persistently infected and showed remarkably high 
p27 values (up to 88%); the three other cats in this group developed a transient viremia 
with lower p27 loads reaching up to 10% (Figure 5a). Three of five cats in group B 
showed a transient viremia with maximal p27 values of 7.9% (Figure 2 and 5b); while 
two cats in group B remained negative for p27 antigen (< 4%) during the 15 weeks post 
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transfusion (Figure 1 and 5b). Moreover, all cats in the negative control group C stayed 
p27 antigen negative during the observation period of 15 weeks (Figure 2 and 5c). 
There was no significant difference concerning the time point, when cats in groups A 
and B became p27 positive. However, 4 weeks post transfusion, significantly more cats 
were p27-positive in group A compared to group B (pF = 0.0476; Figure 2). Thereafter, 
no significant differences were found anymore concerning presence or absence of 
antigenemia between groups A and B. When analyzing the p27 loads, significant 
differences were found in weeks 8 and 9: cats in group A had significantly higher p27 
loads at these time points than cats in group B (pM = 0.0317).  
 
Figure 2: Outcome of FeLV infection in the recipient cats post transfusion. P27 
results from the blood, virus isolation from the blood and virus isolation from the bone 
marrow of the five cats in group A (a), the five cats in group B (b) and the five cats in the 
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negative control group C (c). Four weeks post transfusion, significantly more cats were 
p27-positive in group A compared to group B (pF = 0.0476). 
 
Figure 3: Time course of FeLV infection in the recipient cats. Proviral load of the 
five cats in group A (a), the five cats in group B (b) and the five cats of the negative 
control group C (c). The proviral loads are given as proviral copies/cell. The cats in 
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group B had significantly higher proviral loads in weeks 1 and 2, but lower loads in 
weeks 4, 7 to 12 and 15 (pM < 0.05; indicated with an asterisk). 
 
Figure 4: Time course of FeLV infection in the recipient cats. Plasma viral RNA 
load of the five cats in group A (a), the five cats in group B (b) and the five cats in the 
negativecontrol group C (c). The plasma viral RNA loads are given as copies/ml. The 
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cats in group B had significantly higher viral RNA loads in week 1, but lower loads in 
weeks 7 to 11 (pM < 0.05; indicated with an asterisk). 
 
Figure 5: Time course of FeLV infection in the recipient cats. P27 antigen load of 
the five cats in group A (a), the five cats in group B (b) and the five cats in the negative 
control group C (c). The p27 loads are given as percentage of a positive control run on 
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each plate. Significantly higher p27 loads were found in cats in group A compared to 
cats in group B at weeks 8 and 9 (pM = 0.0317; indicated by an asterisk). 
4.3 Clinical and laboratory findings 
In the clinical examination, two cats in group A (HBZ3, HCC1) and one cat in group B 
(HBU1) showed elevated body temperatures at some time points during the experiment. 
Cat HBZ3 had a body temperature of 39.8°C in week 6 and cat HCC1 had a 
temperature of 40.1 °C in week 8. In these two cats, anorexia and mild lethargy were 
observed during fever depression. The two cats, HCC1 and HBZ3 were treated once 
daily peroral with meloxicam a nonsteroidal drug (Metacam® 0.5 mg/ml cats ad us. vet., 
orale suspension, Boehringer Ingelheim GmbH, Basel, Switzerland) and a total amount 
of 100 ml of Ringer-Lactat (Fresenius Kabi) was infused intravenously in a constant rate 
of 4 ml/kg/h until full recovery. After two days, the cats recovered well and the treatment 
could be stopped. In group B, one cat, HBU1, showed an increased body temperature 
of 39.6 °C in week 3, but did not show any further sings. 
In total, five cats from groups A and four cats from group B developed a general 
lymphadenomegaly of the mandibular, cervicalis superficialis and popliteal lymph node. 
In contrast, in the negative control group C all five cats showed normal lymph node size 
throughout the observation period (Table 3).  
In hematology, three cats in group A showed values outside the reference range. The 
PCV of cat HBZ3 in group A decreased from 28% at week 0 (reference range for kittens 
at the age of 8-20 weeks 33%) to 23% at week 6 and increased again to 33% (within 
normal range) at week 15. After week 3 this cat also demonstrated intermittent 
neutropenia of as low as 0.2 x 103/µl (reference range 2.32 x 103 -10.01 x 103) until 
week 13, when neutrophils returned to normal. In week 4, the PCV of cat HBW2 
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decreased from 31% to 27% and persisted around 29% until week 15. Moreover, cat 
HCC1 had PCV values below the reference range with 24% in weeks 7 and 9; the PCV 
returned to within the reference range at week 11. In addition, in group B a trend (pw = 
0.062) could be observed in that the lymphocytes of all these cats decreased from week 
0 to 1 post transfusion; however, all values remained in the lower region of the 
reference range (Figure 6). 
Furthermore, during weeks 8 and 9 post transfusion, hyperproteinemia (99 g/l; 
reference range 64-80 g/l) and hypoalbuminemia (21 g/l; reference range 30-40 g/l) 
were noticed in the clinical chemistry of cat HCC1 in group A. Serum protein 
electrophoresis analysis revealed hyperbetaglobulinemia and polyclonal 
hypergammaglobulinemia (Figure 7). 
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Table 3: Lymph node evaluation of the 15 recipient cats throughout the 
observation period. 
* Grade assessment: normal lymph node size = -, 1 cm diameter = +, 2 cm diameter = ++, 3 cm 
diameter = +++, ≥ 4 cm diameter = ++++. The diameter specifications are depicted from the 
mean value of the mandibular, cervicalis superficialis and popliteal lymph nodes. 
 
 
 
 
 
 
Group/ 
Cats 
Lymph node size(-/++++)* 
 week 0 1 2 3 4 5 6 7 8 9 10  11  12 13 14 15 
A HBW2 - - - - - - ++ ++ +++ ++ ++ ++ ++ ++ + + 
 HBZ3 - - - - - + + +++ ++ ++ + + + + + - 
 HCC1 - - - - - ++ +++ ++++ ++++ +++ +++ ++ ++ ++ + + 
 HCC4 - - - - - ++ ++ + - - - - - - - - 
 HCD1 - - - - - + - - - - - - - - - - 
B HBU1 - - - - - +++ + + + + + - - - - - 
 HBW1 - - - - - + - - - - - - - - - - 
 HCC3 - - - - - ++ +++ ++ + + + + - - - - 
 HBZ1 - - - - - + - - - - - - - - - - 
 HBY1 - - - - - - - - - - - - - - - - 
C HBU2 - - - - - - - - - - - - - - - - 
 HCC2 - - - - - - - - - - - - - - - - 
 HCD2 - - - - - - - - - - - - - - - - 
 HBZ2 - - - - - - - - - - - - - - - - 
 HBV1 - - - - - - - - - - - - - - - - 
27 
 
 
Figure 6: Lymphocyte counts during the experiment. Five cats in group A (a), the 
five cats in group B (b) and the five cats in the negative control group C (c). Reference 
range in kittens is marked with a gray zone. 
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Figure 7: Serum protein electrophoresis from cat HCC1.  
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4.4  Virus isolation from blood and bone marrow 
Two persistently infected cats (HBW2, HBZ3) were found to be positive in the virus 
isolation from blood. All the other cats including the two FeLV infected blood donors 
remained negative in the virus isolation from blood on the selected time point. 
Latent virus infection in the bone marrow defined as replicating virus upon prolonged in 
vitro culture in the presence of hydrocortisone was observed in six recipient cats 
(HBW2, HBZ3, HCC1, HCD1 in group A and HBU1, HCC3 in group B). All five cats in 
the negative control group C were confirmed to be negative in the virus isolation from 
blood and bone marrow (Table 4). In addition, the blood donor for group B was found 
positive for latent infection, 18 weeks after the blood for the blood transfusion had been 
collected and 60 weeks after FeLV infection). 
4.5 Outcome of the infection  
Recipient cats: The cat HBU1 in group B developed after transient viremia a reactivation 
of the FeLV infection and had to be euthanized due to severe dyspnea in week 26 post 
transfusion (Table 4). A lymphoblastic leukemia (49 x 103 cells/µl with 75% 
lymphoblasts; Figure 8)) and a p27 load of 113% were detected in blood analysis. In the 
histopathological examination a CD3+ T-cell lymphoma of the precordial mediastinum, 
the mesenteric lymph nodes, the liver and the bone marrow was found in this cat 
(Figure 9). In the immunohistology of the bone marrow 25% of lymphoblast cells (CD3+) 
were found.  
Furthermore, cat HCC3 in group B had to be euthanized at week 28 post transfusion 
with pleural effusion due to a CD3+ T-cell lymphoma of the precordial mediastinum 
(Table 4). Additionally, also in the kidney and the lumbar lymph node a CD3+ T-cell 
lymphoma was found during the histopathologic examination. In this case no FeLV 
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reactivation was observed – the cat had remained p27 negative - and all blood 
parameters including complete hematology and clinical chemistry were within the 
reference range.  
In week 31, one of the two persistently infected cats in group A, HBW2, had to be 
euthanized with severe non-regenerative anemia with a PCV of 7% and reticulocytes < 
0.1 (reference range 0-1.0). At the time of euthanasia the p27 antigen load was 114%. 
Blood donors: One of the two transiently FeLV-infected blood donor cats (GCN4, blood 
donor for group B) reactivated the infection and succumbed to FeLV associated disease 
at the time point of the bone marrow collection in week 18 post transfusion (60 weeks 
p.i.; Table 4). Clinically, the cat showed severe dyspnea and was found to have pleural 
effusion. Upon necropsy and immunhistological examination a CD3+ T-cell lymphoma of 
the mediastinum was found. In the hematology no abnormalities were noted but a very 
high p27 load in the plasma of 132% of the positive control was measured. The second 
FeLV-infected blood donor cat (GBX3, blood donor for group A was still healthy and 
remained provirus positive and p27-negative 65 weeks after blood transfusion (107 
week post infection). 
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Figure 8: Cat HBU1 with a lymphoblastic leukemia. Lymphoblast cells are marked 
with an arrow. a) The picture displays a large lymphoblast with moderate amounts of 
basophilic cytoplasm and a large, round nucleus with fine chromatin pattern and several 
large, indistinct nucleoli visible. There is also a medium-sized lymphocyte with moderate 
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amounts of pale basophilic cytoplasm and round nucleus with coarse chromatin pattern. 
b) The picture shows a medium-sized to large lymphoblast with small amounts of 
basophilic cytoplasm and a large, round nucleus with fine chromatin pattern and two 
prominent round nucleoli.  
Figure 9: Cat HBU1 precordial T-cell-Lymphoma: A firm, slightly nodular, whitish 
mass (M) with multiple confluent hemorrhages, measuring approximately 12 x 5 cm 
replaces the precordial mediastinum and obscures physiological structures (thymus, 
sternal lymph nodes). The lung (L) is collapsed and shows partial atelectasis (A) due to 
profound pleural effusion.  
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Table 4: Outcome of the infection with results from virus isolation from blood and 
bone marrow cell culture and clinical outcome of the cats 
 VI B VI BM Outcome of infection* 
 
Blood 
Donors  
 Week 5 17   
Group A GBX3 - - provirus- positive, healthy 
B GCN4 - + † week 60 reactivation: thymic T-cell 
lymphoma 
Recipients  A HBW2 + + † week 31: non-regenerative anemia 
 HBZ3 + + viremic, healthy 
 HCC1 - + provirus-positive, healthy 
 HCC4 - - provirus-positive, healthy 
 HCD1 - + provirus-positive, healthy 
 B HBU1 - + † week 26 reactivation: multicentric T-
cell lymphoma 
 HBW1 - - provirus-positive, healthy 
HBZ1 - - provirus-positive, healthy 
 HCC3 - + † week 28 no reactivation: thymic T-cell 
lymphoma 
HBY1 - - provirus-positive, healthy 
 C HBU2 - - uninfected control, healthy 
 HCD2 - - uninfected control, healthy 
 HCC2 - - uninfected control, healthy 
 HBZ2 - - uninfected control, healthy 
 HBV1 - - uninfected control, healthy 
VI B = Virus isolation from blood 
VI BM = Virus isolation from bone marrow 
* Infection outcome of the cats in the study was determined until week 65 post transfusion 
4.6  Viral shedding and immune response 
Viral RNA loads in saliva could be detected by real-time RT-PCR in all cats in groups A 
and B (Table 5). Particularly high saliva viral RNA loads were found in the two p27 
positive cats, HBW2 and HBZ3. All infected cats with the exception of the two viremic 
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cats (HBW2, HBZ3) developed antibodies to FeLV whole virus (Table 5). In Group C all 
cats remained negative for FeLV.  
 
Table 5: Viral RNA loads in saliva detected by real-time RT-PCR and antibodies to 
FeLV whole virus measured by FL-74 ELISA 
* Copy numbers are depicted per PCR reaction 
  
  viral RNA loads in saliva* Antibodies to FeLV Outcome 
Group Week 0 3 5 7 15  
A HBW2 0 0 321 48,632 - viremic 
 HBZ3 0 2 0 76,074 - viremic 
 HCC1 0 4 2 1,143 + provirus- positive 
 HCC4 0 0 15 150 + provirus- positive 
 HCD1 0 143 858 0 + provirus- positive 
B HBU1 0 17 23 0 + provirus- positive 
 HBW1 0 8 16 0 + provirus- positive 
 HCC3 0 2 12 226 + provirus- positive 
 HBZ1 0 0 4,714 17 + provirus- positive 
 HBY1 0 3 0 2 + provirus- positive 
C HBU2 0 0 0 0 - negative 
 HCD2 0 0 0 0 - negative 
 HBZ2 0 0 0 0 - negative 
 HCC2 0 0 0 0 - negative 
 HBV1 0 0 0 0 - negative 
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5. Discussion 
Our results demonstrated for the first time that FeLV infection can be transmitted via 
blood transfusion from FeLV provirus positive, antigen negative cats to naïve recipients. 
As little as approximately 20,000 proviral copies in 10 ml of blood led to productive 
FeLV infection in the recipient cats. Our results extend earlier results, where proviral 
FeLV DNA in the form of plasmid DNA injected subcutaneously led to infection in 
recipient cats (Chen, Bechtel et al. 1998). Productive infection after intramuscular and 
intradermal injection of a plasmid carrying proviral DNA had also been reported for a 
feline lentivirus, the feline immunodeficiency virus (FIV) (Rigby, Hosie et al. 1997; 
Sparger, Louie et al. 1997), as well as for macaques inoculated intramuscularly with 
simian immunodeficiency virus (SIV) plasmid DNA (Liska, Khimani et al. 1999). Our 
study has direct biological relevance and clinical importance: from our results we 
concluded that there is an imminent risk of FeLV transmission via blood transfusion of 
provirus-positive blood, which needs to be considered in clinic. 
In the cats that received blood carrying proviral DNA and viral RNA (group B), provirus 
was detected in the first week post transfusion and one to three weeks prior cats that 
received only blood with proviral DNA (group A). In addition, cats in group B had higher 
plasma viral RNA loads in week 1 and higher proviral loads in weeks 1 and 2 after the 
transfusion compared to cats in group B. However, by week 4 after transfusion the 
picture had changed and more cats were p27 positive in group A compared to group B 
and viral RNA loads were higher in group A compared to group B. Subsequently, cats in 
group A had higher viral RNA, proviral and p27 loads compared to cats in group B at 
several time points particularly after week 7 post transfusion. Overall, in group A all cats 
became FeLV antigen positive and two cats developed persistent infection, while in 
group B only three cats became transiently antigenemic. A possible explanation for the 
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less grave infection outcome in group B could be a more efficient detection of FeLV by 
the immune system of cats in group B due to the presence of viral RNA and higher 
proviral DNA loads in the transfused blood compared to group A. In contrast, in group A 
the provirus in the donor cells may have been hidden from the immune system of the 
recipient and no viral RNA was present that could have been easily detected early on. 
Thus, the proviral DNA could have undetected infected on this way the host and 
integrate to its genome. However, of note, the infection outcomes, i.e. the number of 
persistently infected cats and of cats developing FeLV-associated disease, were not 
significantly different between the two groups, potentially due to small numbers. 
Symptoms and changes in laboratory parameters compatible with a natural FeLV 
infection were observed in the recipient cats, such as elevated body temperature, 
lymphadenomegaly, anorexia, lethargy and abnormal hematology parameters (anemia, 
neutropenia). The lymph node size was related to the grade of FeLV infection in that 
lymphadenomegaly was more distinct and longer present in cats in group A than in 
group B, and it was especially pronounced in the two viremic cats in group A. Three 
cats in group A showed a mild decrease of the PCV that persisted for several weeks. 
Two of these anemic cats were viremic and one cat showed transiently high p27 antigen 
levels, though this cat resolved antigenemia thereafter. Neutropenia (0.2 x 103/µ) 
occurred in only one of the viremic cats. In the cats in group B, the lymphocyte counts 
decreased in the first week post transfusion, when all cats of this group turned plasma 
viral RNA and provirus positive. Thus, the decrease of the lymphocytes seemed 
associated with the time point of viral infection in the kittens. Clinical disease of FeLV 
infection is characterized by leucopenia, lymphopenia and variable degrees of anemia 
(Hoover and Mullins 1991). A decrease of white blood cells and red blood cells was 
described for viremic cats. However, hematologic abnormalities are mild, absent and 
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mostly transiently in cats that do not have viremia but are only provirus positive. The 
decrease of the red and white blood cells appears due to a suppression of the myeloid 
and erythroid stem cells in the bone marrow (Pedersen, Theilen et al. 1977).  
Replicating virus in the blood could be detected in the two antigenemic cats five weeks 
post transfusion confirming viremia in these cats. In addition 17 weeks after transfusion, 
replicating virus could be isolated from the bone marrow from six recipient cats by cell 
culture assay using hydrocortisone. This included the two viremic cats in group A, but 
also four non-antigenemic cats, where the virus isolation from bone marrow was 
indicative for the presence of latent infection. The positive results from cell culture 
assays further confirmed the replication capacity of FeLV in these six cats after infection 
via blood transfusion of proviral DNA. In addition, all eight cats with regressive infection 
developed antibodies to FeLV whole virus; this further supports that in all these cats 
minimal viral replication took place after transfusion. Subsequently, three out of ten 
recipient cats succumbed to FeLV associated diseases within 31 weeks post 
transfusion. The cats suffered from anemia and lymphoma, which are commonly 
regarded as FeLV associated diseases (Hoover and Mullins 1991). Thus, the infection 
outcome and disease spectrum in the recipient cats mirrors that of a natural FeLV 
infection. 
Two of the provirus-positive cats, one blood donor and one recipient cat, showed 
reactivation of FeLV infection by recurrence of antigenemia. This further emphasizes 
the importance of provirus-positive cats. Provirus-positive cats should be recognized by 
PCR because, subsequent to reactivation, they may pose an exposure risk for 
unprotected cats within the population. In the recipient cat, plasma viral RNA could be 
detected at each time point investigated prior to reactivation. This would further support 
our hypothesis that viral RNA in the blood may be associated with subsequent 
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reactivation of the infection (Hofmann-Lehmann, Cattori et al. 2007). For the blood 
donor cat no samples were available for RT-PCR. The reactivation and subsequent 
development of lymphoma in the blood donor cat raised the question whether collection 
of the large volume of blood increased the risk of reactivation of FeLV infection in the 
blood donor.  
In the saliva of all recipient cats viral RNA was detected post transfusion to varying 
degrees. High loads of saliva viral RNA were mainly noted in the viremic cats but FeLV 
RNA was also observed in cats with regressive infection. This confirms our earlier 
observation (Cattori, Tandon et al. 2009) that during early infection up to 15 weeks after 
FeLV exposure, saliva viral RNA does not seem to be a marker for antigenemia/viremia 
as had been demonstrated for long-term infected cats (Gomes-Keller, Tandon et al. 
2006).  
In small animal clinics, transfusion of blood products is a frequent necessity and has 
become more sophisticated with increased access to blood components, knowledge of 
blood types, cross-matching requirements, the purchase of blood bank products and 
external donor programs (Lanevschi and Wardrop 2001). Although blood transfusions 
are potentially life-saving procedures they carry some risks, such as transfusion 
reactions and especially the potential of transmitting infections (Chiaramonte 2004). 
Transmission of retroviral infections through blood products are already known in 
humans since the first described cases of human deficiency virus 1 (HIV-1) following 
blood transfusion in hemophilic patients in 1982 (CDC 1982). After numerous HIV-1 
transmissions via blood transfusion, the screening of human blood donors was 
conducted by immunoassays to detect viral antibodies or antigens (Stramer, Glynn et al. 
2004). In the late 1980’s, alarming reports of immunosilent HIV (Farzadegan, Polis et al. 
1988; Imagawa, Lee et al. 1989) showing that up to 10% of infected HIV-1 persons may 
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be PCR positive and antibody-negative (immunosilent) carriers were disproved; they 
were found to be due to PCR contamination (Imagawa and Detels 1991; Roy, Damato 
et al. 1993). Detection of early HIV-1 infection during the window period defined as the 
time period between infectivity and the detectability of infection by the immunoassays, 
was performed by p24 antigen screening and recommended by the Food and Drug 
Administration (FDA) in the United States in 1996 (Fiebig, Wright et al. 2003; Stramer, 
Glynn et al. 2004). Later on, the screening of blood donors for HIV-1 tested by nucleic 
acid testing was implemented in a number of developed countries to improve blood 
safety based on the data that HIV-1 RNA screening is more sensitive and able to detect 
infection earlier in the window period than p24 antigen testing (Busch, Kleinman et al. 
2000; Fiebig, Wright et al. 2003; Stramer, Glynn et al. 2004). However, anti-HIV-1 and 
anti-HIV-2 immunoassay or HIV combination antigen-antibody immunoassays are 
recommended to minimize the risk of HIV infection through the route of blood 
transfusion by the World Health Organization (WHO). In a previous study 1 per 3.1 
million donors screened was confirmed to be positive for HIV-1 RNA, therefore blood 
donation testing by nucleic acid testing was useful to prevent iatrogenic transmission of 
HIV-1 (Stramer, Glynn et al. 2004). In lentiviral infection it is unknown whether proviral 
DNA is detectable in the absence of viral RNA. However, for FeLV the incidence of 
proviral DNA without the detection of viral RNA is well described (Hofmann-Lehmann, 
Huder et al. 2001; Torres, Mathiason et al. 2005; Hofmann-Lehmann, Tandon et al. 
2006). A significant number up to 10% of provirus positive cats has been described in 
the cat population of Switzerland (Hofmann-Lehmann, Huder et al. 2001).  
Young cats were chosen for this experiment because they are highly susceptible to 
FeLV infection compared to adult cats (Hoover, Olsen et al. 1976) and they therefore 
rather represent the situation of blood transfusion recipients than healthy adult cats 
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would. We concluded that blood transfusions of an antigen negative but provirus 
positive blood donor may exhibit a potential risk of transmitting FeLV to adult cats. 
Although, older cats become less susceptible to FeLV, at high challenge doses they can 
still be infected. In previous studies efficient natural and experimental infection of adult 
cats was demonstrated (Grant, Essex et al. 1980; Lehmann, Franchini et al. 1991). 
Moreover, recipients of blood transfusions may be particularly prone to infections due to 
preexisting severe clinical conditions and possible immunosuppression, therefore the 
risk of infection may also be high in adult cats. By performing the commonly used blood 
donor screening assay (detection of p27 antigen) both FeLV infected blood donors 
would not have been detected as a potential risk. We highly recommend to screen all 
blood donors, in addition to p27 ELISA, by FeLV provirus-PCR. The use of this 
screening method will prevent inadvertent transmission of FeLV and should be 
performed prior to each blood transfusion. With the results from this study and the 
growing importance of feline blood banks in the future, blood safety for feline patients 
need to be improved (Wardrop, Reine et al. 2005). Therefore, general 
recommendations for the feline blood donor screening need to be adjusted.  
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